This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Poster presentation
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS malignancies consortium clinical trials 010 and 034
1 Weill Cornell Medical College, New York, New York, USA
2 University of Alabama at Birmingham, Birmingham, Alabama, USA
3 Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Headington, Oxford, UK
4 Memorial Sloan Kettering Cancer Center, New York, New York, USA
5 University of California-San Francisco, San Francisco, California, USA
6 Albert Einstein Comprehensive Cancer Center, New York, New York, USA
7 National Cancer Institute, National Institutes of Health Washington, D.C., USA
Infectious Agents and Cancer 2009, 4(Suppl 2):P14 doi:10.1186/1750-9378-4-S2-P14
Published: 17 June 2009First paragraph (this article has no abstract)
Diffuse large B cell lymphoma represents a clinically heterogeneous disease, and several immunohistochemical strategies have been shown to help prognosticate clinical outcome. These include subdivision into germinal center (GC) and non-germinal center (non-GC) subtypes, proliferation index (measured by expression of Ki67), and expression of BCL-2, FOXP1 or Blimp-1/PRDM1. We sought to determine whether immunohistochemical analyses of biopsies from DLBCL patients with HIV infection are similarly relevant for prognostication.